XCath, a medical device company developing neuro-endovascular surgical robotics, has successfully closed a $30 million Series C funding round. The financing, co-led by Crescent Enterprises and Dr. Fred Moll, will accelerate the commercialization of their endovascular robot. This brings XCath's total funding to $92 million.
